The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014

• Published in: PloS one 2015-05, Vol.10 (5), p.e0126920-e0126920
• Main Authors: Brouard, Cécile, Le Strat, Yann, Larsen, Christine, Jauffret-Roustide, Marie, Lot, Florence, Pillonel, Josiane
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; Adolescent; Adult; Adults; Age composition; Aged; Aged, 80 and over; AIDS; Analysis; Blood & organ donations; Chronic infection; Cohort analysis; Cost-Benefit Analysis - statistics & numerical data; Diagnosis; Diagnostic tests; Epidemics; Epidemiology; Eradication; Estimates; Feasibility studies; Female; France - epidemiology; Gender; Health care access; Health surveillance; Hepacivirus - isolation & purification; Hepatitis; Hepatitis C; Hepatitis C, Chronic - diagnosis; Hepatitis C, Chronic - economics; Hepatitis C, Chronic - epidemiology; Hepatitis C, Chronic - virology; Hepatology; HIV; Human immunodeficiency virus; Humanities and Social Sciences; Humans; Incidence; Infections; Infectious diseases; Liver; Male; Mass Screening - economics; Mass Screening - statistics & numerical data; Medical diagnosis; Middle Aged; Models, Statistical; Mortality; Population; Public health; Risk factors; Screening; Serology; Strategy; Studies; Target recognition; Viral infections
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0126920

Recent HCV therapeutic advances make effective screening crucial for potential HCV eradication. To identify the target population for a possible population-based screening strategy to complement current risk-based testing in France, we aimed to estimate the number of adults with undiagnosed chronic HCV infection and age and gender distribution at two time points: 2004 and 2014. A model taking into account mortality, HCV incidence and diagnosis rates was applied to the 2004 national seroprevalence survey. In 2014, an estimated 74,102 individuals aged 18 to 80 were undiagnosed for chronic HCV infection (plausible interval: 64,920-83,283) compared with 100,868 [95%CI: 58,534-143,202] in 2004. Men aged 18-59 represented approximately half of the undiagnosed population in 2014. The proportion of undiagnosed individuals in 2004 (43%) varied from 21.9% to 74.1% in the 1945-1965 and 1924-1944 birth cohorts. Consequently, age and gender distributions between the chronically-infected (diagnosed and undiagnosed) and undiagnosed HCV populations were different, the 1945-1965 birth cohort representing 48.9% and 24.7%, respectively. Many individuals were still undiagnosed in 2014 despite a marked reduction with respect to 2004. The present work contributed to the 2014 recommendation of a new French complementary screening strategy, consisting in one-time simultaneous HCV, HBV and HIV testing in men aged 18-60. Further studies are needed to assess the cost-effectiveness and feasibility of such a strategy. We also demonstrated that data on the undiagnosed HCV population are crucial to help adapt testing strategies, as the features of the chronically-infected HCV population are very distinct.